Familial Exudative Vitreoretinopathies
Conditions
Brief summary
This study aims to investigate the efficacy and safety of bromfenac sodium hydrate eye drops in patients with familial exudative vitreoretinopathy receiving diode laser photocoagulation.
Detailed description
This study aims to evaluate the presence of macular edema as the primary measure and the presence of conjunctival injection as the secondary measure for the investigation of the efficacy of bromfenac sodium hydrate eye drops in patients with familial exudative vitreoretinopathy receiving diode laser photocoagulation.
Interventions
DRUGBromfenac Sodium
The study participants will receive bromfenac sodium hydrate eyedrops twice daily for 14 days.
Sponsors
Seoul National University Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
1 Months to 7 Years
Healthy volunteers
No
Inclusion criteria
* Newly diagnosed patients with familial exudative vitreoretinopathy * Needing diode laser photocoagulation * Consent to the study
Exclusion criteria
* History of corneal diseases * History of hypersensitivity to bromfenac sodium * History of hypersensitivity to non-steroidal anti-inflammatory drugs * Progressive ocular infection * Liver diseases * Hypersensitivity to sulfur dioxide * Receiving anti-coagulation drugs * History of coagulopathies
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Macular edema response rate | 4 weeks after the diode laser photocoagulation | Presence of macular edema |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Conjunctival injection response rate | 4 weeks after the diode laser photocoagulation | Presence of conjunctival injection |
Countries
South Korea
Contacts
Primary ContactJeong Hun Kim, MD, PhD
Outcome results
None listed